![Quiver Logo](/static/img/logo-icon.png)
![YMAB logo](https://quiver-logos.s3.us-east-2.amazonaws.com/ymab.png)
Y-mAbs Therapeutics, Inc. Common Stock
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view YMAB Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of YMAB by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by YMAB's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to YMAB
Recent picks made for YMAB stock on CNBC
ETFs with the largest estimated holdings in YMAB
Flights by private jets registered to YMAB
![Quiver Logo](/static/img/logo-icon.png)